Bortezomib in the treatment of plasma cell myeloma with t(4;14)

Abstract

The t(4;14)(p16;q32) is associated with poor prognosis in the patients diagnosed with plasma cell myeloma (PCM). The introduction of bortezomib has improved overall survival and according to some authors has almost completely overcome the poor prognostic impact of t(4;14). Presented case report is 37-years old patient with newly diagnosed PCM IgG lambda. The induction and consolidation treatment after autologous hematopoietic stem cell transplantation based on bortezomib has resulted in sustained complete response.